Phase1 trial of Panitumumab combined with S-1 and irrinotecan in advanced/metastatic colorectal cancer
Ontology highlight
ABSTRACT: Interventions: Panitumumab:Bi-weekly administration 6 mg/kg TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1,8 every 4 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 125mg/m2, day1
Primary outcome(s): Maximum tolerated dose Recommended dose
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2620191 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA